Latest news with #TTVR
Business Standard
03-06-2025
- Health
- Business Standard
First-Ever Non-Surgical Transcatheter tricuspid Valve Replacement (TTVR-ViV ) Performed in Rajasthan
VMPL Jaipur (Rajasthan) [India], June 3: In a major medical breakthrough for Rajasthan, doctors at Eternal Hospital, Jaipur, have successfully replaced the tricuspid heart valve without open-heart surgery - a first-of-its-kind procedure in the state. Until now, only the aortic and mitral valves could be replaced using transcatheter techniques, but Eternal Hospital's expert heart team has now achieved this milestone with the help of Transcatheter Tricuspid Valve Replacement (TTVR). Dr. Prem Ratan Degawat, Director of Mitral & Tricuspid Valve Therapy, Associate Director TAVR & Senior Structural Heart Disease Expert at Eternal Hospital who performed this procedure said that "The complex procedure was performed on a 57-year-old male patient from Jayal, Nagaur, who had previously undergone two open-heart surgeries - first in 1985 and again in 2017. Due to severe bleeding complications during the second surgery, including heavy bleeding, a third open-heart surgery was considered extremely high-risk. The patient was facing serious health issues, including breathlessness, leg swelling, fluid accumulation in the abdomen, and fluid in the lungs for the past few months. Given his prior surgical history and deteriorating condition, open-heart surgery was ruled out. The heart team at Eternal decided to proceed with TTVR, a cutting-edge, minimally invasive technique in which the damaged tricuspid valve is replaced via catheter - without opening the chest. The entire procedure was completed in just 30 minutes. Fast recovery - Discharged in just three days Dr. Prashant Dwivedi, Director & Incharge for Structural Heart Disease program at Eternal Hospital, shared that the patient made a swift recovery and was discharged within three days of the procedure. He added, "Compared to traditional surgery, TTVR is much safer and allows for quicker recovery. In this case, the patient showed immediate improvement in symptoms." The successful procedure was carried out under the guidance of internationally renowned interventional cardiologist Dr. Samin K. Sharma and senior cardiac surgeon Dr. Ajeet Bana, Cardiac Anaesthetist Dr Navneet Mehta, Dr J S Makkar and Dr Hemant Chaturvedi. A new hope for high-risk patients Mrs. Manju Sharma, Co-Chairperson of Eternal Hospital, said: "Until now, patients who were considered inoperable had very limited options. With TTVR, we now have a new ray of hope for them." Dr. Pracheesh Prakash, CEO of Eternal Hospital, added:
Yahoo
22-05-2025
- Health
- Yahoo
TRiCares presents promising First-In-Human Topaz data at EuroPCR 2025
Early results demonstrate near-complete elimination of tricuspid regurgitation in implanted patients with favorable safety profile and no permanent pacemaker implantations Paris, France and Munich, Germany, 22 May, 2025 – TRiCares SAS ('TRiCares'), a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is presenting data in a late-breaking session at EuroPCR today from its first-in-human trial of Topaz, its Transcatheter Tricuspid Valve Replacement (TTVR) system. Today, Dr Julien Dreyfus, MD, PhD will present 30-day post-procedural data from 20 tricuspid regurgitation (TR) patients treated with Topaz across eight specialist cardiac centers in Europe. The TRICURE First-In-Human study demonstrated significant elimination of TR in treated patients, with grade 'none' (0+) or 'mild' (1+) TR reported in all patients implanted with Topaz. In addition, zero permanent pacemakers were required due to the investigational device. The implantation procedure lasted, on average, 35 minutes. These early clinical results from Topaz compare favorably with existing TTVR treatment approaches, with a procedure that is fast, easy-to-use, and less demanding of imaging specialists. Further details on the data will be shared in today's oral presentation at EuroPCR 2025 and on 'We are highly encouraged by the results of this first-in-human trial. These initial findings serve as important validation for our ongoing clinical trials for Topaz in Europe and the US,' said Ahmed Elmouelhi, President & CEO of TRiCares. 'I want to extend our sincere gratitude to the participating hospitals, the dedicated interventional teams and clinical investigators who contributed to these patient outcomes. To date, the TRiCares team has overseen 60 Topaz implantations, and we continue to work closely with clinicians to refine the procedure and technique.' The initial findings will be used to inform the company's ongoing European pivotal trial (NCT06581471) and U.S. Early Feasibility Study (NCT06506942). EuroPCR presentation details Session: Tricuspid hotline: new devices Title: TRiCares Topaz transfemoral TRICUspid heart valve REplacement system first-in-human trial Presenter: Julien Dreyfus, MD, PhD, FESC, Cardiologist at Centre Cardiologique du Nord, Saint-Denis, France Location: Theatre Bordeaux Date/time: Thursday, 22 May 2025, 08:30 – 09:30 CEST About TRiCaresTRiCares is a privately held company developing Topaz, a minimally invasive tricuspid valve replacement system for the elimination of tricuspid regurgitation (TR). Topaz's unique dual stent design is easy to implant and uses established transfemoral and transjugular delivery methods, avoiding the need for high-risk open-heart surgery. Topaz is designed to fit a wide range of anatomies and replaces the diseased tricuspid valve. Once in place, it flexes with every heartbeat. A European Pivotal Study and a US/Canadian Early Feasibility Study are underway, with progress being made towards FDA approval and CE marking. TRiCares has focused on TR since its inception and its ambition is for Topaz to become the valve of choice for the millions of TR patients worldwide, overcoming the limitations of current treatment approaches. TRiCares is a global business, with offices in France, Germany, the US and Brazil, and is supported by a strategic partner and leading life science venture capital firms: 415 Capital, Andera Partners, Bayern Kapital, BioMed Partners, Credit Mutuel Innovation, GoCapital, Karista, and Wellington Partners. About TopazThe Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System is designed to eliminate tricuspid regurgitation through a minimally invasive approach. This system consists of the Topaz Heart Valve Prosthesis and a catheter-based implantation system. It is developed exclusively for use in the tricuspid position and to provide a system for physicians that is safe and easy to implant. The unique two-stent valve prosthesis is inserted primarily via the femoral vein and transports the prosthesis into the right side of the heart, where it is finally released to replace the diseased tricuspid valve. For further information please contact: TRiCares SASAhmed Elmouelhi, President & CEOinfo@ ICR Healthcare Lucy FeatherstoneT: +44 (0)20 3709 5700tricares@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
